🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia

Assessment of Senl_B19 CAR-T Cells in Relapsed/Refractory CD19+ B-ALL NCT07244406Phase 21 site📍 Beijing Hebei Senlang Biotechnology Inc., Ltd. · Tests: S1904 CD19 CAR-T CD19x22 Chimeric Antigen Receptor T-cell Therapy (CAR T) in Pediatric B-ALL NCT06559189Phase 11 site📍 Aurora University of Colorado, Denver · Tests: CD19x22 CAR T A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005) NCT07570173Phase 2, Phase 328 sites📍 Toronto📍 Copenhagen📍 Aarhus Nord Merck Sharp & Dohme LLC · Tests: MK-1045, Blinatumomab, Acetaminophen, Diphenhydramine, Dexamethasone Bridging Allogeneic Hematopoietic Stem Cell Transplantation or Not After CD19 CAR - T (S1904) Cell Therapy for r/r B-cell Acute Lymphoblastic Leukemia NCT06581081NA1 site📍 Beijing Peking University People's Hospital · Tests: Senl_B19 autologous CAR-T (S1904) treatment A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL) NCT06173518Phase 114 sites📍 Los Angeles📍 Palo Alto📍 Aurora Autolus Limited · Tests: AUTO1 Pomalidomide After CAR T-cell Therapy for the Treatment of Relapsed or Refractory CD19+ B-cell Leukemia or Lymphoma NCT07532525Phase 11 site📍 Ann Arbor University of Michigan Rogel Cancer Center · Tests: Biospecimen Collection, Pomalidomide A Study of CTA101 UCAR-T Cell Injection in Patients With Relapsed or Refractory CD19+ B-line Hematological Malignancy NCT04227015EARLY Phase 11 site📍 Hangzhou He Huang · Tests: CTA101 Nanobody-Based CD19/CD22 Tandem Dual CAR-T Therapy for R/R B-ALL NCT06880913Phase 1, Phase 21 site📍 Beijing Peking University People's Hospital · Tests: Nanobody-Based CD19/CD22 Tandem Dual CAR-T UCD19 CarT in Treatment of Pediatric B-ALL and B-NHL NCT04544592Phase 1, Phase 21 site📍 Aurora University of Colorado, Denver · Tests: CD19CAR-CD3Zeta-4-1BB-Expressing Autologous T-Lymphocyte Cells A Study of Murine CD19 CAR-T Therapy for Patients With Relapsed or Refractory CD19+ B-cell Hematological Malignancies NCT04532281EARLY Phase 11 site📍 Hangzhou Zhejiang University · Tests: Murine CD19 CAR-T cells Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia NCT03136146Phase 21 site📍 Houston M.D. Anderson Cancer Center · Tests: Bortezomib, Clofarabine, Cyclophosphamide, Dexamethasone, Etoposide Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies NCT07523555Phase 1, Phase 21 site📍 Shenzhen Beijing Biotech · Tests: Autologous CD19/CD22 dual-target CAR-T module, Autologous CD19/CD20 dual-target CAR-T module, Autologous BCMA/CD19 dual… HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological Malignancies NCT05658640Phase 1, Phase 236 sites📍 Vienna📍 Ghent📍 Copenhagen Princess Maxima Center for Pediatric Oncology · Tests: Trametinib, Dexamethasone, Cyclophosphamide, Cytarabine, Intrathecal chemotherapy HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies NCT05751044Phase 1, Phase 233 sites📍 Vienna📍 Ghent📍 Copenhagen Princess Maxima Center for Pediatric Oncology · Tests: Dasatinib, Venetoclax, Dexamethasone, Cyclophosphamide, Cytarabine Tafasitamab (MOR00208) in Pediatric Patients With Relapsed or Refractory Acute B Lineage Leukemia NCT05366218Phase 1, Phase 211 sites📍 Freiburg im Breisgau📍 Tübingen📍 Ulm University Hospital Tuebingen · Tests: Tafasitamab Safety and Efficacy of CAR T Cell Therapy in Patients with R/r B-ALL NCT06635330Phase 1, Phase 21 site📍 Tehran Kara Yakhteh Tajhiz Azma Company · Tests: anti-CD19 CAR T cell therapy CART19 Cells Effects in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Non-Hodgkin's Lymphoma NCT05054257Phase 11 site📍 Prague Institute of Hematology and Blood Transfusion, Czech Republ… · Tests: Autologous CAR19 T lymphocytes Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR NCT03676504Phase 1, Phase 22 sites📍 Heidelberg📍 Heidelberg University Hospital Heidelberg · Tests: CD19.CAR T Cells, Fludarabine, Cyclophosphamide Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19) NCT06533579Phase 1, Phase 211 sites📍 Duarte📍 Los Angeles📍 Denver Vironexis Biotherapeutics Inc. · Tests: Dose Level 1, VNX-101, Dose Level 2, VNX-101, Dose Level 3, VNX-101, Dose Level 4, VNX-101 Clinical Study of SYNCAR-100 in the Treatment of Relapsed/Refractory Acute B-Lymphoblastic Leukemia NCT07429461EARLY Phase 11 site📍 Hangzhou Zhejiang University · Tests: SYNCAR-100 Injection Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01) NCT04150497Phase 1, Phase 219 sites📍 Los Angeles📍 Aurora📍 Denver Cellectis S.A. · Tests: UCART22, CLLS52 JY231(JY231) Injection for the Treatment of Relapsed/Refractory B Cell Lymphoma/ Leukemia NCT06940960NA1 site📍 Guangzhou Affiliated Hospital of Guangdong Medical University · Tests: JY231 Injection Safety, Tolerability, and Pharmacokinetics of Donor-derived CD19 CAR Therapy Bridged Allo-HSCT and Sequential Donor-derived CD22 CAR Therapy for r/r B-ALL: a Clinical Trial NCT06326008Phase 11 site📍 Beijing Beijing GoBroad Hospital · Tests: Donor-derived CD19 CAR Therapy Bridged Allo-HSCT and Sequential Donor-derived CD22 CAR Therapy A Study of CAR-T Cells Therapy for Patients With Relapsed and/or Refractory Central Nervous System Hematological Malignancies NCT04532203EARLY Phase 11 site📍 Hangzhou Zhejiang University · Tests: CAR-T cells, Ommaya Reservoir JY231(JY231) Injection for the Treatment of Relapsed or Refractory B Cell Lymphoma/ Leukemia NCT06689917NA1 site📍 Wuhan Tongji Hospital · Tests: JY231 Injection Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL) NCT03666000Phase 115 sites📍 Tampa📍 Atlanta📍 Atlanta Imugene Limited · Tests: Azer-cel, Fludarabine, Cyclophosphamide, IL-2, Ibrutinib, Acalabrutinib, Zanubrutinib, or Pirtobrutinib Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies NCT05418088Phase 12 sites📍 Columbus📍 Columbus Sumithira Vasu · Tests: Anti-CD19/CD20/CD22 CAR T-Cells, Cyclophosphamide, Fludarabine Phosphate, Echocardiography, Multigated Acquisition Scan Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies NCT05476770Phase 131 sites📍 Los Angeles📍 Orange📍 San Francisco Therapeutic Advances in Childhood Leukemia Consortium · Tests: Tagraxofusp, Fludarabine, Cytarabine, Dexamethasone, Vincristine A Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of B019 Injection in Subjects With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia. NCT06927466Phase 18 sites📍 Beijing📍 Nanchang📍 Nanchang Shanghai Pharmaceutical Group Biological Therapy Technology… · Tests: B019 Safety and Efficacy of PRG-2302 for Refractory or Relapsed B-cell Acute Lymphoblastic Leukemia Disease. NCT06659653EARLY Phase 11 site📍 Jinzhou Tan Jie · Tests: PRG2302
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy